Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Citation Metrics and Productivity

Amanda S. Mixon (MD, geriatrician-investigator; ORCID 0000-0003-2365-9329) has 104 works with ~1,860 citations and h-index 25 per OpenAlex (slightly higher than the Semantic Scholar figures of h=23, 1,609 citations, 94 papers), indicating consistent, verifiable impact OpenAlex profile: h-index 25, 104 works. Her trajectory shows rising output: 13 works in 2023 and 23 in 2024, with strong annual citation flows (e.g., 349 in 2016, 362 in 2023) driven by the durable MARQUIS and geriatric syndromes literature.

Most Cited Contributions

Her citation core is geriatric care-transition safety. The most cited first-author work is Characteristics Associated With Postdischarge Medication Errors (Mayo Clinic Proceedings, 88 citations), and she co-authored the widely cited Geriatric Syndromes in Hospitalized Older Adults Discharged to Skilled Nursing Facilities (JAGS, 106 citations) and the MARQUIS2 toolkit implementation study First-author study on postdischarge medication errors Geriatric syndromes at SNF transition. Flagship trials include the Shed-MEDS deprescribing RCT (JAMA Internal Medicine, 84 citations), the PREVENTABLE pragmatic statin trial design paper (86 citations), and the VOICE opioid-reduction and buprenorphine randomized trials PREVENTABLE pragmatic trial design. More recent work extends into machine learning for venous thromboembolism prediction and AI-driven clinical decision support, signaling methodological broadening.

Critical Assessment and Blind Spots

Strengths: Deep, coherent program in deprescribing, medication reconciliation, and care transitions spanning qualitative, implementation-science, and RCT designs; sustained VA/Vanderbilt collaborations; first- and senior-authorship on key papers (e.g., first author on postdischarge medication errors and discharge preparedness) First-author discharge preparedness study. Limitations: Citation density is respectable but not exceptional; several core trials (MARQUIS, Shed-MEDS) show modest or process-level effects on patient safety outcomes, and much output is protocols, design papers, and qualitative/implementation studies that inflate work counts relative to definitive outcome trials. Replication across non-VA, non-academic systems remains uncertain, and OpenAlex missing primary-institution metadata suggests incomplete affiliation data — a known database limitation. Overall: a solid, genuinely impactful mid-career clinical implementation scientist rather than a field-defining researcher.

 BGPT Author Review

Scientific Quality

h-index 25 with ~1,860 citations and 104 works reflects solid, sustained impact for a mid-career clinical investigator. She designs and executes genuine RCTs (Shed-MEDS, VOICE, CORPs) and pragmatic trials (PREVENTABLE), not merely observational studies. Weaknesses: many interventions yield modest or process outcomes; heavy reliance on VA/Vanderbilt ecosystems limits external validity; a substantial fraction of output is protocols, design papers, and secondary analyses rather than decisive hypothesis-testing studies.

Communication Quality

Prolific in both qualitative and quantitative reporting, publishing in readable clinical venues (JAGS, JHM, Mayo Clinic Proceedings) with stakeholder- and patient-facing framing (telehealth perspectives, health literacy-informed communication). Deduction: numerous protocol/design/letter-style outputs and some duplicated titles across venues slightly fragment the narrative.

Author Novelty

Shed-MEDS pioneered hospital-initiated-to-postacute deprescribing — a genuinely novel intervention niche — and her ML/VTE prediction and AI decision-support work is contemporaneous rather than pioneering. Much surrounding output refines established implementation frameworks (RE-AIM, intervention mapping) rather than generating new theory.

Scientific Rigor

RCTs with published statistical analysis plans (MODE trial), validated instruments, on-treatment and site-level analyses of MARQUIS, and explicit study of non-participation bias in deprescribing trials indicate methodological care. Deductions: many designs are qualitative or single-site QI projects vulnerable to selection and Hawthorne effects; pragmatic trials trade internal control for generalizability; effect sizes of medication reconciliation interventions are often small or process-oriented.